Key Takeaways

CAIRNS, April 26 – Tuberculosis (TB) remains one of the deadliest infectious diseases known to humankind. The existing TB vaccine is highly protective, but it has some limitations.

Global rollout of rapid molecular tests for TB over the last 12 years: Cochrane Review summarizes research on recipient and provider views

The International Union Against Tuberculosis and Lung Disease (The Union) released its first quarterly training and education newsletter, sharing the latest news and updates from Union courses.

One of the most intriguing findings from South Africa’s first National TB Prevalence Survey was that out of 234 people found to have TB, 58% had abnormal chest X-rays without experiencing any TB symptoms. The short report in which the findings were made public recommended the expanded use of X-ray technology for TB screening.

The World Health Organization (WHO) Global Tuberculosis Programme, in collaboration with University College London and other partners, convened a virtual technical consultation from 15 to 17 September 2021 that focused on innovative clinical trial designs that could be used for evaluating new tuberculosis (TB) preventive treatments (TPTs).

[NEW DELHI] Climatic factors such as dew point temperature, relative humidity and atmospheric temperature that affect water droplet formation are crucial for the survival and spread of tuberculosis (TB), an airborne infectious disease, say researchers.

The registration for the 53rd Union World Conference on Lung Health is NOW OPEN! The conference will take place virtually on 8-11 November 2022.

Romania has the highest TB burden in the European Union/European Economic Area (EU/EEA) comprising almost a quarter of the reported patients in 2017, and a TB notification rate six times higher than the EU/EEA average.

Messenger ribonucleic acid — known as mRNA — was discovered in the 1960s, but it has reached new heights of popularity among vaccine developers due to its flexibility and adaptability to emerging infectious diseases.